Company news
Tenaya Therapeutics, Inc. news in 2025
Tenaya Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Tenaya Therapeutics Announces Proposed Public Offering
December 11, 2025
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC
December 11, 2025
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
December 11, 2025
Tenaya Therapeutics Announces Pricing of Public Offering
December 10, 2025
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 10, 2025
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
November 8, 2025
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
November 4, 2025
Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
October 9, 2025
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
October 2, 2025
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 18, 2025
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
September 2, 2025
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
August 31, 2025
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 8, 2025
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 6, 2025
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
July 30, 2025
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
May 13, 2025
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
April 24, 2025
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
March 31, 2025
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
March 24, 2025
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
March 19, 2025
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
March 3, 2025
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
February 2, 2025
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
January 12, 2025
Decks in 2025
- Technical Presentation (August 2025)
Technical · 30 slides · Aug 26, 2025
- Investor Presentation (April 2025)
Investor deck · 50 slides · April 2025
- Technical Presentation (2025)
Technical · 15 slides · 2025